Meta menu:

From here, you can access the Emergencies page, Contact Us page, Accessibility Settings, Language Selection, and Search page.

Open Menu

The Deubzer Lab

The Deubzer laboratory conducts basic and translational research centered around advancing diagnostics and therapeutics to treat children with high-risk cases of neuroblastoma.

You are here:

What is neuroblastoma?

Neuroblastoma is a solid tumor that develops from precursor cells of the sympathetic nervous system. Neuroblastomas develop along the sites of the sympathetic ganglia in the body, not in the brain. It affects primarily children under six years of age, and accounts for 11% of all cancer-related deaths in children.

Research Topics

Our Research - Schematic

We use cutting-edge molecular technologies to provide the basis for advancing molecular medicine for our patients. The number of long-term survivors of high-risk disease remains discouraging despite considerable international efforts to improve outcome over the last decades, with survival rates as low as 40% and below 10% in the relapse situation. We currently pursue three lines of research to overcome this dreadful scenario:

  1. Exploiting the potential of liquid biopsies to develop predictive diagnostics
  2. Characterizing the metabolome to contribute to biomarker development and therapy
  3. Identifying molecular key players for drug development

The five most important publications of the Deubzer Lab

Fabian J, Opitz D, Althoff K, Lodrini M, …, Eggert A, Witt O, Schulte JH, Deubzer HE. MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma. Oncotarget. 2016 Aug 27. Pubmed

Lodrini M, Poschmann G, Schmidt V, Wünschel J, …, Eggert A, Deubzer HE. Minichromosome maintenance complex is a critical node in the miR-183 signaling network of MYCN-amplified neuroblastoma cells. J Proteome Res 2016;15(7):2178-86. Pubmed

Fabian J, Lodrini M, Oehme I, Schier MC, Thole TM, …, Deubzer HE. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3. Cancer Res 2014;74(9):2604-16. Pubmed

Oehme I, Linke JP, Böck BC, Milde T, …, Deubzer HE, Witt O. Histone deacetylase 10 promotes autophagy-mediated cell survival. Proc Natl Acad Sci U S A. 2013;110(28):E2592-601. Pubmed

Lodrini M, Oehme I, Schroeder C, Milde T, …, Deubzer HE. MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. Nucleic Acids Res. 2013 Jul;41(12):6018-33. Pubmed

Selected cooperation partners

Prof. Dr. Nils Blüthgen, Charité – Universitätsmedizin Berlin, Institute for Theoretical Biology

Dr. Katleen de Preter, Prof. Dr. Frank Speleman, Prof. Dr. Jo Vandesomple, Ghent University Hospital, Center for Medical Genetics

Dr. Barbara Hero, Prof. Dr. Matthias Fischer, Prof. Dr. Thorsten Simon, University Children's Hospital Cologne, Department of Pediatric Hematology and Oncology

Prof. Dr. Thomas Höfer, German Cancer Research Institute (DKFZ), Division of Theoretical Systems Biology

Dr. Anja Heeren-Hagemann, Charité – Universitätsmedizin Berlin, Department of Pediatric Hema- tology, Oncology and Stem Cell Transplantation, Zebrafish-Unit

Prof. Dr. Michael Hummel, Charité – Universitätsmedizin Berlin, Institute for Pathology, Laboratory for Molecular Pathology

Prof. Dr. Ulrich Keilholz, Charité – Universitätsmedizin Berlin, Charité Comprehensive Cancer Center (CCCC)

Dr. Stefan Kempa, Berlin Institute for Medical Systems Biologie, Proteomics/Metabolomics

Prof. Dr. Annette Kopp-Schneider, German Cancer Research Center (DKFZ), Department of Biostatistics

Dr. Annette Künkele, Charité – Universitätsmedizin Berlin, Department of Pediatric Hematology, Oncology and Stem Cell Transplantation

Prof. Dr. Matthias Selbach, Max-Delbrück Center for Molecular Medicine (MDC), Department of Protein Dynamics

Prof. Dr. Johannes Schulte, Charité – Universitätsmedizin Berlin, Department of Pediatric Hematology, Oncology and Stem Cell Transplantation

PD Dr. Ingeborg Tinhofer-Keilholz, Charité – Universitätsmedizin Berlin, Laboratory for Radiation Biology

The copyright of the logos lies with the respective institution.